The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview by Quiñonero Muñoz, Francisco José et al.
REVIEW
The challenge of drug resistance in pancreatic ductal
adenocarcinoma: a current overview
Francisco Quiñonero1,2,3*, Cristina Mesas1,2,3*, Kevin Doello1,3,4, Laura Cabeza1,2,3, Gloria Perazzoli1,3, Cristina
Jimenez-Luna5, Ana Rosa Rama6, Consolación Melguizo1,2,3, Jose Prados1,2,3
1Institute  of  Biopathology  and  Regenerative  Medicine  (IBIMER),  Center  of  Biomedical  Research  (CIBM),  University  of
Granada,  Granada  18100,  Spain; 2Department  of  Anatomy  and  Embryology,  Faculty  of  Medicine,  University  of  Granada,
Granada  18071,  Spain; 3Instituto  Biosanitario  de  Granada  (ibs.  GRANADA),  Granada  18014,  Spain; 4Medical  Oncology
Service, Virgen de las Nieves Hospital, Granada 1812, Spain; 5Department of Oncology, Ludwig Institute for Cancer Research,
University of Lausanne, Epalinges 1066, Switzerland; 6Department of Health Science, University of Jaén, Jaén 23071, Spain
 
ABSTRACT Pancreatic  ductal  adenocarcinoma  (PDAC)  has  one  of  the  highest  mortality  rates  among  all  cancer  types.  Its  delayed  diagnosis
precludes  curative  resection,  thus  most  of  the  current  therapies  against  PDAC  are  based  on  chemo-  and  radiotherapy.
Unfortunately,  these  strategies  are  insufficient  to  improve its  poor  prognosis.  Despite  the  advances  made in  chemotherapy (e.g.
nab-Paclitaxel  and  Gemcitabine),  many  patients  with  PDAC  are  unable  to  benefit  from  them  due  to  the  rapid  development  of
drug  resistance.  Currently,  more  than  165  genes  have  been  found  to  be  implicated  in  drug  resistance  of  pancreatic  tumors,
including different integrins, mucins, NF-κβ, RAS and CXCR4. Moreover, drug resistance in PDAC is thought to be mediated by
the  modulation  of  miRNAs  (e.g.  miRNA-21,  miRNA-145  and  miRNA-155),  which  regulate  genes  that  participate  in  cell
proliferation,  invasion  and  metastasis.  Finally,  cancer  stem  cells  are  intimately  related  to  drug  resistance  in  PDAC  due  to  their
ability  to  overexpress  ABC  genes  -involved  in  drug  transport-,  and  enzymes  such  as  aldehyde  dehydrogenases  -implicated  in
cellular  drug  metabolism-  and poly  (ADP-ribose)  polymerases  -involved  in  drug-induced  DNA damage  repair-.  Understanding
the mechanisms involved in drug resistance will contribute to the development of efficient therapeutic strategies and to improve
the prognosis of patients with PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) has one of the
highest mortality rates among all cancer types and increases
its incidence year by year. The 5-year survival rate is only 5%,
even in patients undergoing complete tumor resection or
treated with chemo- and radiotherapy1. PDAC is the most
frequent type of pancreatic cancer (PC), affecting 90% of
patients with cancer in the pancreas, and it is the third cause
of cancer-related death in the United States, following lung
and colorectal  cancer  PDAC has  no  visible  symptoms or
biomarkers,  which  hinders  its  early  diagnosis1-2.  As  a
consequence,  more  than  50%  of  patients  present  with
metastatic disease at diagnosis, when no curative treatment
can  be  offered.  Many  of  the  currently  used  drugs  may
increase the lifetime of patients and relieve their symptoms,
but neither cancer eradication nor complete symptomatic
relief is usually possible. Few drugs have been shown to be
effective against PC over the years. Gemcitabine, a nucleoside
analogue used since the 90s as the clinical agent of reference2
is  the most common chemotherapy agent used in clinical
practice. Unfortunately, low survival rates are still achieved
with this drug. To increase treatment efficiency, formulations
of Gemcitabine encapsulated in albumin nanoparticles have
been assayed in  vitro  and in  vivo3.  On the other  hand,  5-
fluorouracil (5-FU), a molecule widely used in colon cancer
treatment due to its capacity to be inserted into the DNA and
inhibit cell proliferation, lacks a therapeutic efficacy in PC,
where  no  significant  improvement  in  symptoms  or  life
expectancy was demonstrated4. Clinical studies reporting the
use of 5-FU along with Gemcitabine did not show clinical
benefits in comparison with Gemcitabine alone, but a slight
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increase in side effects (neutropenia, diarrhea and anemia)
was  reported5.  However,  FOLFIRINOX,  a  formulation
containing  several  drugs  (including  5-FU),  increased  the
survival  of  patients  with  advanced  PC  by  two  months6
Irinotecan,  an  inhibitor  of  Topoisomerase  I  present  in
FOLFIRINOX, showed effectiveness in the treatment of this
type  of  cancer  in  some  clinical  trials7,  and  its  liposomal
encapsulation would improve the treatment of  refractory
PC8. Finally, Paclitaxel associated with human albumin (nab-
Paclitaxel) is also being used in PC9. Recently, a clinical trial
demonstrated  that  nab-Paclitaxel  plus  Gemcitabine
improved the survival of patients with advanced PC by two
months,  without  significantly  increasing  drug  toxicity10.
Currently, the most effective therapies in clinical terms are
nab-Paclitaxel,  Gemcitabine and FOLFIRINOX. However,
this regime is not applicable to all patients given the increase
in toxicity and the severe risk for patients in advanced stages
of the disease.
In most cases, PC progresses to infiltration of other organs
and distant metastasis, which have a high impact on survival.
In these patients, conventional treatment does not improve
the prognosis. A cornerstone of this therapeutic failure is the
development  of  drug  resistance.  Accumulating  evidence
suggests  that  chemoresistance  is  intimately  linked  to  the
disruption  of  multiple  genes  involved  in  intracellular
signaling,  DNA repair,  metabolism and regulation of  cell
replication11. In addition, local recurrence of the tumor after
surgical  resection,  chemo-  and/or  radiotherapy  has  been
related to the presence of cancer stem cells (CSCs). These
cells  are characterized by a  high treatment resistance and
proliferation capacity, which explains the more aggressive
nature of the recurrent tumor12.  In this review we analyze
different genetic and protein resistance mechanisms by which
PDAC cells reduce the efficacy of the available drugs, and the
advances  being  made  to  avoid  such  drug  resistance  and
decrease the current mortality rate of PC.
Drug resistance at the molecular level
Although currently Gemcitabine is the first-line treatment
against PDAC, many patients are unable to benefit from it
due to the rapid development of resistance to this drug by the
tumor  cells11.  Gene  expression  microarray  analyses
performed  in  PC  cell  lines  showed  more  than  165  genes
related to drug resistance. These genes were involved in a
myriad  of  cell  functions,  including  antioxidant  activity,
apoptosis, cell cycle regulation and transduction of signals,
among  others13  (Figure  1).  Gemcitabine  inhibits  cell
proliferation and induces apoptosis of tumor cells through
the activation of the AMPK / mTOR pathway, increasing the
expression of AMPK and decreasing that of mTOR, which
results  in  cell  autophagy14.  In  this  route,  ARK5,  a  kinase
related  to  AMPK,  induces  the  epithelial-mesenchymal
transition  (EMT)  of  PC  cells,  which  is  linked  to  drug
resistance. Recently, the inhibition of ARK5 by modulating
the  oxygen  conditions  (normoxia/hypoxia)  proved  to
sensitize pancreatic cells to Gemcitabine15. The SRC tyrosine
kinase, which has been used as a prognostic marker in PC,
may also be involved in drug resistance of PC cells16. In fact,
some natural compounds that act over this molecule were
able  to  suppress  tumor  growth  and  decrease  the
chemoresistance  of  tumor  cells  against  Gemcitabine17.
Similarly,  the  overexpression of  integrin  β1,  an adhesion
molecule involved in the interaction between cells and the
extracellular  matrix,  has  been  linked  to  chemotherapy
resistance in solid cancers, including PDAC18. This integrin
induced Gemcitabine resistance by activating CDC42 and the
PI3K pathway19, which regulate the cell cycle and apoptosis20.
Finally, mutations in the RAS proto-oncogenes -detected in a
high proportion of  human pancreatic  tumors-  have been
associated with drug resistance21. The RT11-i (an antibody
that inhibits the RAS / RAF / MEK and PI3K / AKT signaling
pathways) reduced Gemcitabine-resistance in PC cell lines22.
In addition, the inhibition of RAB14, a member of this family
of proteins, decreased the IC50 of Gemcitabine and increased
apoptosis induction23.
On  the  other  hand,  two  of  the  most  important
glycoprotein  families,  i.e.  ABC  transporters  and  mucin
proteins,  have  been  related  to  PDAC  resistance.  ABC
transporters extrude drugs out of the cell, decreasing their
intracellular  concentration.  Cancer  cells  expressing  these
transporters are generally referred to as multidrug resistant
(MDR) cells24-25. In this vein, overexpression of the ABCB1
gene  was  found  to  be  deregulated  in  pancreatic  tumors
originated due to overexpression of the MYC oncogene26.
Similarly, MUC1 overexpression induces the expression of
s e v e r a l  d r u g - r e s i s t a n c e  g e n e s  i n  p a n c r e a t i c
adenocarcinoma27. In addition, this glycoprotein induces the
expression of HIF1α  and increases the metabolic rate and
internalization  of  glucose.  These  processes  have  been
implicated  in  an  increased  resistance  to  Gemcitabine28.
Moreover, the deregulation of MUC4, a member of the MUC
family, has been related to the first disturbances that result in
carcinogenesis  and  drug  resistance  in  PC29.  In  fact,  the
overexpression  of  MUC4  was  associated  with  a  negative
regulation  of  the  expression  of  a  nucleoside  transporter
(hCNT1) involved in cell internalization of Gemcitabine30-31.
Some nuclear transcription factors have been implied in
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drug resistance, as is the case with kappa β (NF-κβ), which
modulates  the  immune and inflammatory  responses32-33.
Similarly,  a  factor related to NF-κβ,  named TRIM31, was
associated with a more aggressive phenotype of PC in which
anti-apoptotic genes involved in Gemcitabine-resistance were
overexpressed.  Therefore,  a  therapeutic strategy based on
specific  TRIM31  inhibitors  could  be  useful  to  decrease
Gemcitabine-resistance in PC34-35. In addition, Gemcitabine
can induce the expression of NF-κβ  and generate reactive
oxygen  species  (ROS)  through  the  activation  of  the  P22
factor.  The  expression  of  NF-κβ  regulates  the  signaling
pathway of CXCR4, another factor that confers resistance
against  Gemcitabine36.  The  chemokine  receptor  CXCR4,
involved in the first stages of organ development, is of great
importance in the tumor genesis and metastatic spread of
PC37. Its overexpression is associated with a worse prognosis,
probably because the overactivation of the CXCL12-CXCR4
signaling axis confers resistance against current therapies38-39.
The basis of this resistance is that CXCR4 negatively regulates
the expression of let-7a miRNA, which is responsible for the
inhibition  of  cell  proliferation,  metastasis  and  drug
resistance39.  Another  nuclear  factor  that  induces  drug
resistance is CHK1, a protein able to inhibit the progression
of the cell cycle in response to DNA damage. Inhibitors of
CHK1 proved to decrease tumor cell resistance and favor the
action of  antiproliferative drugs (i.e.  Gemcitabine) in PC
cells.  Conversely,  the  inhibition  of  HSP90  -a  CHK1-
activating protein- did not increase the sensitivity of PC cells
to Gemcitabine40. Recently, HSP27, another member of this
family,  has  been  demonstrated  to  be  implicated  in
Gemcitabine resistance41-42.
Role of NCRNAS in drug resistance
The  ENCODE  project  estimates  that  non-coding  RNA
(ncRNA) transcripts constitute approximately 70% of the human
genome,  having  a  number  of  cell  regulatory  functions.
Within ncRNAs, miRNAs regulate 90% of gene expression
and influence the processes of cell proliferation, invasion and
metastasis. Subsequently, miRNAs have been implied in the
diagnosis and prognosis of several cancer types, including
PDAC43-45. In addition, some specific miRNAs play a role in
the development of drug resistance in PC (Table 1).
For  example,  miRNA-21  proved  to  increase  drug
resistance through the inhibition of FasL expression, a factor
that  triggers  apoptosis.  This,  in  turn,  is  associated with a
decrease in patient  survival46.  Furthermore,  the ability  of
miRNA-21  to  induce  drug  resistance  in  tumor  cells  is
 
Figure 1     Different mechanisms of drug resistance in pancreatic cancer that comprise tissular hypoxia increasing HIF-1 levels and
diminishing reactive oxygen species (ROS), a dense extracellular matrix which impedes the diffusion of chemotherapeutic agents, the
existence of cancer stem cells that escape to apoptosis, deregulated molecular signal pathways such as RAS, NFkB and PI3K pathways and,
overcoat KRAS and BRCA genetic deregulation.
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mediated  by  the  PI3K-AKT  pathway,  whose  activation
decreases cell susceptibility to apoptosis through an increased
expression  of  the  anti-apoptotic  gene  Bcl247-48.  Likewise,
miRNA-29c seems to play a role in chemoresistance of PC
cells. Its overexpression is associated with increased levels of
USP22, which proved to induce autophagy and inhibition of
apoptosis  following  treatment  with  Gemcitabine49-50.
Moreover, the inhibition of miRNA-145 and the increase in
miRNA-155 expression have been also related to PDAC drug
resistance. The former, a tumor suppressor that increases the
sensitivity  of  tumor  cells  to  Gemcitabine,  inhibits  the
signaling pathway of p70S6K1, a protein implicated in drug
resistance, tumor growth and metastasis51-52.
The  latter  is  involved  in  the  increase  in  cellular  anti-
apoptotic activity53 and in the deregulation of the DCK gene
expression (implied in the metabolism of Gemcitabine54. In
addition,  miRNA-155 induces  the  secretion of  exosomes,
increases  the  expression of  ROS detoxification genes  and
decreases DCK expression53-54. Finally, the overexpression of
miR-365 through the repression of the pro-apoptotic genes
SHC1 and BAX induced Gemcitabine-resistance in PC cells55.
Drug resistance in PDAC has been also associated with
miRNAs.  For  example,  miRNA-181c,  which  is  highly
expressed  in  advanced  stages  of  PC,  increases  the
chemoresistance against Gemcitabine, 5-FU and Paclitaxel by
the inactivation of the Hippo antitumor signaling pathway56.
Interestingly, the lncRNA GAS5, an ncRNA of more than 200
bp,  antagonizes  the  effect  of  miRNA-181c and should be
explored as a therapeutic strategy57. Moreover, miRNA-221-
3p and MiR-320a have been implicated in 5-FU resistance.
The former desensitizes PC cells to 5-FU through negative
regulation of RB1, a tumor suppressor gene which has been
implicated in the development of PC58.  The latter inhibits
PDCD4, another tumor suppressor gene that increases the
expression  of  molecular  markers  related  to  the  EMT,
promotes the proliferation and migration of tumor cells and
makes them more invasive59-60. In fact, PDCD4 is regulated
by  several  miRNAs  such  as  miR18361  miRNA-2162  and
miRNA-42963, which may repress PDCD4 expression in PC
cell lines, promoting tumor growth. Finally, the deregulation
of miRNA-506 -which acts as a tumor suppressor- boosts the
progression of pancreatic tumors, increasing chemoresistance
through the modification of the signaling pathway in which
NF-κβ participates64. In sum, a large number of micro-RNAs
are involved in the development of PDAC, acting in certain
cases  as  proto-oncogenes  or  tumor  suppressor  genes
depending on the signaling pathways regulated.
Epithelial-mesenchymal transition
and drug resistance
Correct adhesion of tumor cells to the cellular matrix is a
Table 1   miRNAs involved in drug resistance in pancreatic cancer
Name Expression Gene(s) regulated Effect Drug(s) involved Reference
miR-21 Overexpressed FasL, PDCD4, PTEN (inh), Bcl2
(exp)
Inhibition of apoptotic and tumor
suppressor genes
Gemcitabine, 5-FU 46-48,62
miR-29c USP22 (exp) Autophagic process and inhibition of
apoptotic process
Gemcitabine 49,50
miR-155 DCK, ROS detoxification genes
(exp)




miR-365 SHC1 (inh), BAX (inh) Inhibition of pro-apoptotic genes 55
miR-429 PDCD4 (inh) Inhibition of tumor suppressor gene 63
miR-181c CTGF, BIRC5, BLC2L1, YAP, TAZ
(exp)
Inactivation of antitumor pathway





miR-221-3p RB1 (inh) Inhibition of tumor suppressor gene 5-FU 58
miR-320a PDCD4, β-cadherin, E-cadherin
(inh), fibronectin,N-cadherin,
Vimentin, ZEB1, Snail2 (exp)
Induction of epithelial-mesenchymal
transition and inhibition of tumor
suppressor genes
60
miR-145 Underexpressed RPS6KB1 (inh), miRNA-155 (exp) Inhibition of cell migration, tumor
growth and metastasic process
Gemcitabine 51,52
miR-506 SPHK1, Akt, NF-κB (exp) Induction of tumorigenic pathway 64
inh: inhibited genes dependent on miRNA expression; exp: overexpressed genes dependent on miRNA expression.
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hallmark of cancer progression. However, many of chemo-
and  radiotherapy-resistant  tumors  have  been  proved  to
originate  blood  circulating  tumor  cells  from  an  EMT
process65.  Cancer  stem  cells  (CSCs)  are  essential  in  the
genesis  of  tumors,  and  they  produce  a  large  number  of
signaling substances involved in cell proliferation and drug
resistance. Interestingly, the cells activated during the process
of EMT display a gene expression profile similar to that of
CSCs, which would explain their ability to form new tumors
with great resistance to chemo- and radiotherapy66. In fact,
Hangbin et al. were able to sensitize Gemcitabine-resistant
cell  lines  through  the  inhibition  of  EMT  by  means  of
hyperthermia67.  One  of  the  metabolic  pathways  more
involved in EMT and drug resistance is PI3K/AKT/mTOR.
The  deregulation  of  this  pathway  causes  a  decrease  in
chemotherapy-induced DNA damage, inhibition of apoptosis
and a decrease in the expression of E-cadherin –a molecule
associated with EMT-. The use of an inhibitor against this
signaling  pathway  allows  to  inhibit  the  EMT  and  the
migration  of  cancer  cells,  subsequently  inhibiting  tumor
growth, metastasis and EMT in murine models68. Another
gene related to  EMT is  Slug,  a  transcriptional  factor  that
suppresses E-cadherin expression, which confers resistance to
Gemcitabine  in  pancreatic  CSCs  through EMT.  Thus,  its
suppression at the transcriptional level makes it possible to
increase the sensitivity of PC cell lines, reducing their invasive
and  migratory  capacity69.  Although  different  molecular
pathways regulate EMT, miRNAs are essential factors in the
control of this process. In this vein, miR-509-5p and miR-
1243 inhibit the EMT process and their overexpression in PC
cells  increases  the  sensitivity  to  Gemcitabine70-71.  In
conclusion, the use of miRNA inhibitors of EMT, one of the
processes that mostly influences drug resistance in PDAC,
opens new possibilities in the treatment of this entity.
Role of cancer stem cells in drug
resistance
For  many  years,  cancer  was  thought  to  be  composed  of
clonal, homogeneous cell populations. Nevertheless, over the
years it became evident that tumors are highly heterogeneous
systems  constituted  by  cells  with  varying  degrees  of
differentiation. In fact, it was observed that CSCs, a group of
poorly-differentiated  cells,  are  responsible  for  the  self-
renewal capacity of tumors12. The presence of highly drug-
resistant  CSCs  in  the  tumor  is  a  cornerstone  in
understanding its recurrence (i.e. tumor relapse after chemo-
or radiotherapy),  a  phenomenon associated with a  worse
prognosis72.  Although several resistance mechanisms have
been  described,  three  systems  must  be  highlighted  with
regard  to  PDAC:  overexpression  of  ABC  transporters,
detoxifying  enzymes  and  proteins  involved  in  cell  death
processes73.
ABC transporters
The family  of  ABC transporters  is  present  in  most  living
beings, from the simplest forms of life (bacteria) to the most
complex  organisms  (mammals).  These  molecules  are
involved in the transport of different metabolites between the
cell  membrane  and  the  extracellular  matrix  against  the
concentration gradient, using the energy released from the
hydrolysis of ATP. Their main functions are detoxification,
prevention of intracellular oxidative stress and cell protection
against xenobiotics74. However, their detoxification activity
serves  as  an  escape  mechanism  for  antitumor  drugs  and
increases resistance to chemotherapy agents (Figure 2).
This  resistance  is  mainly  mediated  by  three  receptors:
MDR1, BCRP and MRP175. In addition, a high expression of
the MRP4 protein has been detected in PDAC. This protein
promotes  cell  proliferation  and  plays  a  role  in  the  rapid
formation  of  colonies  from  tumor  cells76.  Other  genes
involved in the synthesis of ABC transporters, such as ABCB4/
11,  ABCC1/3/5/10  and ABCG2 are  also  overexpressed  in
PDAC tissues77.  Interestingly,  CSCs  from PC showed  an
increased expression of ABC transporters, which is associated
with  a  worse  response  to  chemotherapy.  In  particular,
ABCB1  –which  originates  a  protein  known  as  p-
glycoprotein-  is  of  major  relevance  in  PDAC  as  it  is
considered  the  ABC  transporter  more  involved  in  drug
resistance, not only in this tumor but in many other cancer
types78.
Aldehyde dehydrogenases
The  aldehyde  dehydrogenases  (ALDH)  are  a  family  of
enzymes whose function is to oxidize cellular aldehydes to
carboxylic acids.  These aldehydes are originated from the
metabolism of several cellular components (proteins, nucleic
acids) that often remain as cellular waste,  and need to be
eliminated. One of the primary functions performed by these
enzymes concerns the metabolism of  retinol  (vitamin A),
which  is  converted  into  retinoic  acid.  This  molecule  is
essential  for  an adequate  embryonic  development,  which
makes a high expression of ALDH essential in stem cells79.
On the other hand, a great variety of aldehydes are generated
from the metabolism of environmental agents and drugs, and
they  may  induce  cell  damage  and  death.  Therefore,  the
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overexpression of these enzymes protects against these toxic
agents  and  promotes  cell  survival.  In  experiments  using
PDAC cell lines, overexpression of ALDH enzymes allowed
to identify cell  populations capable of originating tumors
more efficiently80.
Although there are several enzyme isotypes, the ALDH1A1
gene  has  commonly  served  as  a  marker  to  differentiate
normal from CSCs in adult tissues81. Besides, the ALDH1B1
isotype is generally used as a marker of stem cells in the early
stages of pancreas development and only a small population
of cells that overexpress this marker remains in the adult82.
This isotype also promotes tumor proliferation. Accordingly,
two phenotypes  of  PC can be  distinguished:  those  whose
growth is favored by the overexpression of ALDH1A1, and
those  with  a  dominant  ALDH1B1  phenotype83.  The
inhibition of ALDH1A1 in PDAC cell lines proved to increase
sensitivity  to  Gemcitabine,  indicating  that  ALDH1A1
overexpression  may  be  paramount  for  drug  resistance
maintenance  in  tumor  cells84.  In  addition,  Gemcitabine-
resistant  PDAC  cells  showed  a  higher  expression  of
membrane  markers  also  present  in  CSCs  -including
ALDH1A1- and an overexpression of the SRC oncogene. The
use of an SRC inhibitor along with Gemcitabine proved to
inhibit  tumor  proliferation,  decreasing  the  expression of
ALDH1A1  and  the  number  of  CSCs  in  the  tissue.  This
indicates that the expression of ALDH1A1 is of significance
in both normal and cancer stem cells for the preservation of
their phenotype85-86.
The PARP enzyme family
Poly (ADP-ribose) polymerases (PARPs) constitute a family
of 18 proteins with a conserved catalytic domain capable of
transferring several ADP-ribose units to their target proteins.
They are involved in several cellular processes, including the
regulation  of  proliferation  and  programmed  cell  death.
Moreover,  two  of  the  most  important  members  of  this
family,  PARP1  and  PARP2,  play  a  role  in  DNA  repair87.
Through their catalytic activity, these enzymes modify certain
factors responsible for the recruitment of proteins involved
in efficient DNA repair (Figure 3). PARP1 is overexpressed
in pluripotent cells and its correct expression is essential for
maintaining the unique characteristics of human stem cells,
including CSCs. Its mechanism of operation is based on the
addition of  several  units  of  ADP-ribose  using NAD+  as  a
substrate,  resulting in a poly (ADP-ribose) chain that can
contain up to 200 units88. PARP1 modifies p53 and inhibits
its binding to the genes that regulate the process of apoptosis.
 
Figure 2   ABC transporters in detoxification of chemotherapeutic drugs in pancreatic cancer. The most common drugs are oxaliplatin
(OXA), 5-fluorouracil (5-FU), gemcitabine (GEM), irinotecan (IRI) and Nab-paclitaxel (Nab-PTX). The main ABC transporters (ATP binding
cassette) in pancreatic cancer was breast cancer resistant protein (BCRP), P- glycoprotein (P-gp) and multidrug resistance protein (MRP).
MRP and BCRP transporters require the conjugation with glutathione.
Cancer Biol Med Vol 16, No 4 November 2019 693
The inhibition of  p53  and the  repair  of  DNA damage  by
PARP may act as mechanisms of drug resistance89.
The overexpression of  PARP1 has been associated with
different  cancer  types  in  humans,  including  liver,  lung,
endometrium, ovary and skin90. In 2010, it was discovered
that the inhibition of PARP1 diminished cell proliferation in
hepatocellular carcinoma by modulating the expression of
genes implicated in tumor development and vasculogenesis91.
Given the importance of PARP1/2 in DNA damage repair,
several  drugs  aiming  to  inhibit  their  activity  have  been
designed as a plausible strategy against cancer. This is the case
with Olaparib, an inhibitor of both PARP1 and PARP2 that
induces S and G2/M arrest and apoptosis. Olaparib has been
approved  by  the  FDA since  2014  for  the  maintenance  of
patients with ovarian cancer who have mutations in BRCA1
and  BRCA292.  Simultaneous  inhibition  of  PARP1  and
RAD51  proteins,  which  are  capable  of  interacting  with
BRCA2 during homologous recombination, has the potential
to sensitize cells to radiation therapy, leading to cell  cycle
arrest and apoptosis93. The use of small molecules that mimic
the state of mutated BRCA2 can disrupt the BRCA2-RAD51
interaction, increasing Olaparib effectiveness and allowing
the treatment of patients with wild BRCA294.  In addition,
specific inhibitors against the BET protein family are able to
reduce the expression of RAD51, thus increasing sensitization
to PARP1/2 inhibitors95. Furthermore, PARP1/2 inhibitors
have  been  used  to  delay  DNA  damage  repair,  allowing
sensitization to proton beam irradiation96.  Finally,  PARP
inhibitors  have  been  combined  with  agents  that  inhibit
telomerase, an enzyme responsible for maintaining telomere




Despite the large number of research lines dedicated to PC,
the efficiency of current therapies remains too low. In order
to  avoid  drug  resistance,  new  formulations  are  being
developed  based  on  traditional  drugs.  One  of  the  main
 
Figure 3   Mechanism of action of PARP (poly-ADP-ribose-polymerase). Single strand DNA damage induced by chemotherapeutic agents
or radiotherapy is repaired by this enzyme leading to cell survival. In this process PARP accumulates ADP tails. However, big amounts of
DNA damage cannot be repaired by PARP, so that, ADP tails are released and induce cell death (A). Mechanism of synthetic lethality. BER
(Base Excision Repair) system repairs single chain DNA damage and HRS (Homologous Recombination System) repair double strand DNA
damage. These two systems are consecutive, so that, DNA damage and the ineffective of BER lead to the activation of HRS. HRS is made up
by repair proteins like BRCA, ATM or ATR. Germinal of somatical mutations in these genes provoke an ineffective HRS dependent DNA
repair. This fact is profited to trigger a syntetic lethality, inhibiting PARP with molecules such as olaparib. Therefore, the deffective HRS due
to genetic mutations added to BER system inhibition by PARP blockers lead to apoptosis of cancer cells (B).
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problems with Gemcitabine is that its blood concentration is
maintained  for  a  short  period  of  time,  as  the  cytidine
deaminase breaks it down in just one hour. Therefore, other
formulations have been tested to increase drug efficiency. In
this vein, the use of PEGylated liposomes allowed to reach a
similar tumor concentration of Gemcitabine with a 10-fold
lower dose, reducing its rapid blood degradation98. Likewise,
the use of albumin nanoparticles along with Gemcitabine
decreased its toxicity and improved its biodistribution and
efficiency in in vitro and in vivo assays using PDAC cells99.
Other nanoparticles containing Gemcitabine and antisense
oligonucleotides against the proto-oncogene miR-21 were
found to have a high inhibitory effect on the proliferation of
PC cells100.
The addition of  Gemcitabine to  cell  cultures  causes  an
increase in ROS, leading to apoptosis. However, this process
is  not  totally  efficient  due  to  the  existence  of  ROS
detoxification  enzymes  capable  of  eliminating  these
molecules.  To cope with this  mechanism of resistance,  Ju
et  al.101  proposed  to  target  the  molecular  pathways  that
regulate the expression of detoxification enzymes and use
inhibitors  against  some  of  these  systems  (e.g.  GSH).
Meanwhile, Aibani et al. prevented chemoresistance in PC
cells  by encapsulating three drugs (5-FU, Leucovorin and
Doxorubicin) in PEG particles102. Finally, the use of a plant-
derived compound (β-sitosterol) together with Gemcitabine
allowed to efficiently induce apoptosis in pancreatic cell lines
through cell  cycle arrest in G0/G1 and led to decrease the
IC50  of Gemcitabine, revealing a synergistic effect of both
drugs103.
On the other hand, different strategies have been carried
out to overcome drug resistance in PC at a clinical stage. For
instance, EMT inhibition using antisense oligonucleotides
such as Trabedersen has shown positive results in phase I/II
clinical trials104. Hyaluronic acid, one of the components of
the  extracellular  matrix,  plays  an  important  role  in  drug
resistance  in  pancreatic  adenocarcinoma.  Accordingly,
hyaluronic acid-degrading enzymes (e.g. hyaluronidase) have
been combined with chemotherapeutic agents to improve
treatment efficacy, although contradictory outcomes have
been reported.  In  fact,  while  phase  II  clinical  trials  using
Gemcitabine/Abraxane and hyaluronidase showed significant
improvements  in  terms  of  progression-free  survival,  the
combination  of  FOLFIRINOX  and  hyaluronidase  led  to
poorer overall survival rates105-106.
Finally,  although  chemotherapy  remains  as  the  main
treatment in PC, novel immunotherapy-based strategies are
showing  encouraging  results107.  Immunotherapy  aims  to
boost the immune response, subsequently increasing tumor
cell identification and elimination by the immune system.
This  can  be  achieved  by  means  of  both  passive  (e.g.
antibodies, activated T-cell transfer) and active techniques
(e.g. vaccines)108. However, pancreatic adenocarcinoma has
many properties that prevent its recognition by the immune
system, including lack of  tumor-infiltrating lymphocytes,
highly  dense  extracellular  matrix,  and  production  of
immunosuppressive  cytokines  by  PC  cells.  These  factors
explain  why  novel  immunotherapy  treatments  (e.g.
Ipilimumab,  Nivolumab,  Pembrolizumab) are  not  totally
effective at present109.
Conclusions
Although  remarkable  progress  has  been  made  in  cancer
research  within  the  last  decade,  PDAC  still  has  very  low
survival rates. The current inability for early detection limits
the  application  of  effective  treatments.  In  addition,  the
development of drug resistance is a key factor to understand
the  failure  of  current  therapy  in  both  the  tumor  and
metastatic tissues. Drug resistance is mediated by different
mechanisms,  such  as  gene  mutations  involved  in  critical
metabolic  pathways  and  ncRNAs  that  modulate  the
expression of genes implied in cell behavior. On the other
hand, CSCs from PDAC show a high drug resistance owing
to  several  reasons,  including  overexpression  of  PARP
enzymes,  ABC transporters  involved in  drug  elimination
from the cell, and intracellular detoxification enzymes such
as ALDHs. Therefore, the increase in survival of patients with
PDAC should occur not just by means of discovering early
serum  markers,  but  rather  due  to  the  development  of
therapeutic strategies aimed to eliminate pancreatic CSCs
and minimize drug resistance.
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